|
June 2008
Avastin prolongs survival in colorectal cancer
June 30, 2008
ZURICH (Reuters) - A new phase III study of Roche's Avastin (bevacizumab) shows significantly improved survival in patients with metastatic colorectal cancer irrespective of K-Ras gene mutations, the Basel-based drug maker said on Monday.
Metastatic potential may be inherent in DCIS cells
June 30, 2008
NEW YORK (Reuters Health) - Ductal carcinoma in situ (DCIS) cells may be able to invade, and perhaps metastasize, from the outset rather than being transformed to acquire this behavior.
Nephron-sparing surgery effective for multiple ipsilateral renal tumors
June 30, 2008
NEW YORK (Reuters Health) - Nephron-sparing surgery is safe and effective for selected patients with multiple ipsilateral renal tumors, according to a report in the June BJU International.
Molecular breast imaging more cost-effective than MRI without loss of sensitivity
June 30, 2008
NEW YORK (Reuters Health) - Research presented at the Department of Defense's annual Era of Hope breast cancer meeting indicates that molecular breast imaging (MBI) appears to have comparable sensitivity and specificity to magnetic resonance imaging (MRI) in the detection of breast cancers, but is more cost-effective.
Abnormal p53 boosts prostate cancer recurrence
June 30, 2008
NEW YORK (Reuters Health) - Prostate cancer is more likely to recur in men with abnormal p53 protein expression compared with their counterparts without this abnormality, according to researchers.
Plasma biomarkers identified in early stage pancreatic cancer
June 30, 2008
NEW YORK (Reuters Health) - Proteins differentially expressed in a mouse model of pancreatic ductal adenocarcinoma are also present in early-stage disease in humans, scientists report in the June issue of PLoS Medicine.
Prostate screening of obese men calls for PSA adjustment
June 27, 2008
NEW YORK (Reuters Health) - Men with increased body mass index (BMI) generally have relatively low prostate specific antigen (PSA) levels even when prostate findings are abnormal -- and thus cancers may be missed or not detected promptly -- according to US and Canadian researchers.
Merck's Gardasil not cleared for older women
June 25, 2008
NEW YORK (Reuters) - U.S. regulators have told Merck & Co they cannot yet approve Merck's application to expand marketing of its HPV vaccine Gardasil to an older group of women, the drugmaker said Wednesday.
Nelfinavir added to chemotherapy shows promise for pancreatic cancer
June 24, 2008
NEW YORK (Reuters Health) - A combination of the protease inhibitor nelfinavir and a conventional chemotherapy regimen of gemcitabine and cisplatin plus radiotherapy has "acceptable toxicity and promising activity" in patients with locally advanced pancreatic cancer, European investigators say.
Asians least likely to receive CRC screening in US
June 24, 2008
NEW YORK (Reuters Health) - Asians are less likely than non-Hispanic whites and other racial/ethnic minorities to undergo colorectal cancer (CRC) screening, according to physicians at the University of California, Davis School of Medicine in Sacramento.
NSAIDs offer no protection against melanoma
June 24, 2008
NEW YORK (Reuters Health) - Despite laboratory evidence that nonsteroidal anti-inflammatory drugs (NSAIDs) could play a role in prevention of melanoma, a prospective observational study failed to find any evidence in support of such an association.
Approach enlists immune system to fight leukemia
June 20, 2008
CHICAGO (Reuters) - Leukemia patients may be able to avoid developing resistance to the drug Gleevec through a mathematical formula that predicts when they should receive an immune-boosting vaccine, researchers said on Thursday.
Healthy lifestyle triggers genetic changes: study
June 17, 2008
WASHINGTON (Reuters) - Comprehensive lifestyle changes, including a better diet and more exercise, can lead not only to a better physique but also to swift and dramatic changes at the genetic level, U.S. researchers said on Monday.
U.S. FDA cautions consumers against cancer 'cures'
June 17, 2008
WASHINGTON (Reuters) - Consumers should beware of products sold on the Internet that claim to cure cancer, U.S. health officials said on Tuesday, threatening penalties against more than two dozen companies selling creams, tea and pills as treatments for the disease.
New inhibitors of breast cancer cells identified
June 17, 2008
NEW YORK (Reuters Health) - A team of U.S. scientists has identified a new family of compounds that block the ability of estrogen to stimulate the growth of breast cancer cells.
Radiation may help after prostate cancer setback
June 17, 2008
NEW YORK (Reuters Health) - Men whose prostate cancer recurs after they have undergone surgical removal of the prostate may benefit from early radiation therapy, according to study findings reported in this week's Journal of the American Medical Association.
HER-2 has less prognostic value in inflammatory breast cancer
June 17, 2008
NEW YORK (Reuters Health) - HER-2 status does not appear to affect recurrence-free survival in women with inflammatory breast cancer, according to a report in the May 1st issue of Cancer.
Methotrexate for arthritis raises melanoma risk
June 12, 2008
NEW YORK (Reuters Health) - Patients with rheumatoid arthritis who are treated with methotrexate appear to have an elevated risk of developing melanoma compared with the general population, according to the findings of an Australian study.
Proscar lowers prostate cancer risk in all men
June 12, 2008
NEW YORK (Reuters Health) - Finasteride (Proscar) reduces the risk of prostate cancer in all men, regardless of their risk level for the disease, new research shows.
Comfort should be focus of late ovarian cancer care
June 12, 2008
NEW YORK (Reuters Health) - The results of a new study suggest that even aggressive treatments do not improve survival for women with advanced ovarian cancer. Thus, the focus should be on making the patient's remaining days as comfortable as possible.
Lapatinib as effective as hormone therapy in advanced renal cell cancer
June 10, 2008
NEW YORK (Reuters Health) - In patients with advanced renal cell carcinoma, lapatinib provides results comparable to hormone therapy, and may do even better in those whose tumors overexpress epidermal growth factor receptor (EGFR), according to European researchers.
Walking may improve fatigue in leukemia patients undergoing chemotherapy
June 10, 2008
NEW YORK (Reuters Health) - A walking exercise program can improve fatigue-related experiences in patients with acute myelogenous leukemia (AML) undergoing chemotherapy, according to the results of a study published in the May issue of the Journal of Pain and Symptom Management.
New melanoma drugs - why do so few benefit?
June 4, 2008
CHICAGO (Reuters) - When they work, new melanoma treatments that enlist the help of the immune system to attack tumors can have a stunning effect, in some cases arresting the deadly skin cancer for four years.
KRAS mutation status predicts cetuximab efficacy in colorectal cancer
June 3, 2008
NEW YORK (Reuters Health) - Patients with newly diagnosed metastatic colorectal cancer whose tumors contain a normal (wild-type) KRAS gene are most likely to benefit from the addition of cetuximab (Erbitux) to standard FOLFIRI chemotherapy as part of first-line treatment, according to data highlighted at the American Society of Clinical Oncology annual meeting this week.
Single-dose carboplatin as effective as radiation for early testicular cancer
June 3, 2008
NEW YORK (Reuters Health) - In men with surgically resected stage I seminoma, a single dose of carboplatin chemotherapy is as effective as 2 to 3 weeks of radiation therapy in preventing recurrence and is much less toxic, according to study findings presented at the American Society of Clinical Oncology annual meeting in Chicago.
|
